Heart and heart-lung transplantation have been established as effective treatments for a wide variety of end-stage cardiopulmonary diseases. Recent years have seen refinements in surgical techniques for cardiopulmonary replacement as well as the selection and postoperative care of thoracic transplant recipients. Despite substantial clinical progress, however, significant problems remain, particularly donor organ shortage, graft rejection, opportunistic infection, and limited organ preservation techniques. Basic and clinical research are currently addressing these problems. In this brief review, we provide an update of our experiences with heart and heart-lung transplantation in the West (particularly at Stanford University), an outline of the active issues in the field, and some thoughts about the development of thoracic transplantation in Asia.
Get full access to this article
View all access options for this article.
References
1.
HosenpudJNovickRBreenTDailyO. The registry of the international society for heart and lung transplantation: eleventh official report - 1994. J Heart Lung Transplant1994;13(4):561–70.
2.
ReitzBBurtonNJamiesonSHeart and lung transplantation: autotransplantation and allotransplantation in primates with extended survival. J Thorac Cardiovasc Surg1980;80:360.
3.
ReitzBPennockJShumwayN. Simplified operative method for heart and lung transplantation. J Surg Res1981;31:1.
4.
ReitzBWallworkJHuntSHeart-lung transplantation: successful therapy for patients with pulmonary vascular disease. N Eng J Med1982;306:557.
5.
SarrisGE. Cardiac transplantation in the cyclosporine era: the Stanford experience. J Thorac Cardiovasc Surg1994;108:240.
6.
MuraliSKormosRUretskyBPreoperative pulmonary hemodynamics and early mortality after orthotopic cardiac transplantation: the Pittsburgh experience. Am Heart J1993;126:896–904.
7.
HarjulaAJLBaldwinJCGlanvilleARTazelaarHOyerPEStinsonEBShumwayNE. Human leucocyte antigen compatibility in heart-lung transplantation. J Heart Transplant1987;6:162.
8.
President's Commission. Guidelines for the determination of death. JAMA1981;246:2184–7.
9.
BaiK. The definition of death: the Japanese attitude and experience. Transplant Proc1990;22:991–2.
10.
HandaH. Diversification in the concept of “birth and death”: the controversy about “brain death and organ transplantation” in Japan. Surg Neurol1993;39:437–9.
11.
KoyamaIHoshinoTNagashimaNAdachiHUedaKOmotoR. A new approach to kidney procurement from non-heart-beating donors: core cooling on cardiopulmonary bypass. Transplant Proc1989;21:1203–5.
12.
Alvarez-RodriguezJdel Barrio-YesaRTorrente-SierraJPrats-SanchezGuzman A. Posttransplant long-term outcome of kidneys obtained from asystolic donors maintained under extracorporeal cardiopulmonary bypass. Transplant Proc1995;27:2903–5.
13.
SzostekMDanielewiczRLagiewskaBSuccessful transplantation of kidneys harvested from cadaver donors at 71 to 259 minutes following cardiac arrest. Transplant Proc1995;27:2901–2.
14.
ShirakuraRKamiikeWMatsumuraAMultiorgan procurement from non-heart-beating donors by use of Osaka University cocktail, Osaka rinse solution, and the portable cardiopulmonary bypass machine. Transplant Proc1993;25:3093–4.
15.
de BegonaJGundrySRazzoukABoucekMMKawauchiMBaileyL. Transplantation of hearts after arrest and resuscitation: early and long-term results. J Thorac Cardiovasc Surg1993;106:1196–201.
16.
JonesGHurleyJ. The effect of prostacyclin in the adhesion of leucocytes to injured vascular endothelium. J Pathol1984;115:51–9.
17.
MoncadaSFlowerRVaneJ. Prostaglandins, prostacyclin, thromboxane A2 and leukotrienes In: GilmanAGoodmanLRallTMuradF ed. The pharmacologic basis of therapeutics. New York: Macmillan, 1985:660–73.
18.
NovickRReidKDenningLProlonged preservation of canine lung allografts: the role of prostaglandins. Ann Thorac Surg1991;51:853–9.
19.
FantoneJFunkelSWardPZurierR. Suppression by prostaglandin E1 of vascular permeability induced by vasoactive inflammatory mediators. J Immunol1980;125:2591–6.
20.
VaneJ. Adventures and excursions in bioassay — the stepping stones to prostacyclin. Postgrad Med J1983;59:743–58.
21.
HallTBorkonAGurtnerGImproved static lung preservation with corticosteroids and hypothermia. J Heart Transplant1988;7:348.
22.
MatsumuraANakaharaKMiyoshiSFiltration coefficient in isolated preserved and reperfused canine lung. J Surg Res1991;50:205.
23.
HooperTJonesMThomsonDModulation of ischemic lung injury by corticosteroids. Transplantation1990;50:530.
24.
LowerRRShumwayNE. Studies on the orthotopic homotransplantation of the canine heart. Surg Forum1960;11:18.
25.
AngermanCSpesCTammenAAnatomic characteristics and valvular function of the transplanted heart: transthoracic versus transesophageal echocardiographic findings. J Heart Transplant1990;9:331–8.
26.
KendallSCiulliFMullinsPBiocinaBDunningJLargeS. Total orthotopic heart transplantation: an alternative to the standard technique. Ann Thorac Surg1992;54:187.
27.
LickSDCopelandJGRosadoLJArabiaFASethiGK. Simplified technique of heart-lung transplantation. Ann Thorac Surg1995;59:1592.
28.
ReichenspurnerHMillerJRobbinsRGirgisRYuhKBerryGTheodoreJReitzBA. RATG-inducrtion therapy significantly reduces incidence of acute pulmonary rejection compared to OKT3 treatment. J Heart Lung Transplant1996;15:S103.
29.
ValentineVGRobbinsRCBerryGJPatelHRReitzBATheodoreJ. Actuarial survival of heart-lung and bilateral sequential lung transplant recipients with obliterative bronchiolitis. J Heart Lung Transplant1995;14:S66.
30.
GrattanMTMoreno-CabralCStarnesVACytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA1989;261:3561.
31.
ScottJPHigenbottamTWSharplesLRisk factors for obliterative bronchiolitis in heart-lung transplant recipients. Transplantation1991;51:433.
32.
ReichenspurnerHGambergPYunKGirgisRHuntSValantineHOyerPERobbinsRCReitzBA. Inhaled amphotericine B prophylaxis significantly reduces the number of fungal infections after heart-, lung-, and heart-lung transplantation. J Heart Lung Transplant1996;15:S56.
33.
HertzMJessurunJKingMSavikSMurrayJ. Reproduction of the obliterative bronchiolitis lesion after heterotopic transplantation of mouse airways. Am J Path1993;142:1945–51.
34.
HuangXReichenspurnerHShorthouseRMorrisR. Heterotopic tracheal allograft transplantation: a new model to study the molecular events causing obliterative airway disease in rats. J Heart Lung Transplant1995;14:S49.
35.
ReichenspurnerHHuangXSoniVShorthouseRBerryGMorrisR. Pathogenesis and treatment of obliterative airway disease after heterotopic tracheal allograft and xenograft transplantation. Surg Forum1995;46:456–8.
36.
WinterJGouwAGroenMRespiratory viral infections aggravate airway damage caused by chronic rejection in rat lung allografts. Transplantation1994;57(3):418–22.
37.
KeenanRLegaMDummerJCytomegalovirus serologic status and postoperative infection correlated with risk of developing chronic rejection after pulmonary transplantation. Transplantation1991;51(2):433–8.
38.
DuncanSGrgurichWIaconoAA comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation. Am J Respir Crit Care Med1994;150:146–52.
39.
SarrisGSmithJBernsteinDPediatric cardiac transplantation: the Stanford experience. Circulation1994;90:II-51–5.
40.
StarnesVMarshallSLewistonNTheodoreJStinsonEShumwayN. Heart-lung transplantation in infants, children, and adolescents. J Ped Surg1991;26:434–8.
BernsteinDKollaSMinerMCardiac growth after pediatric heart transplantation. Circulation1992;85:433–9.
43.
SarrisGSmithJShumwayNLong-term results of combined heart-lung transplantation: the Stanford experience. J Heart Lung Transplant1994;13:940.
44.
TheodoreJMorrisABurkeCCardiopulmonary function at maximum tolerable constant work rate exercise following human heart-lung transplantation. Chest1987;92:433.
45.
YuhDGandyKHoytGReitzBRobbinsR. Tolerance to cardiac allografts induced in utero with fetal liver cells. Circulation1995;92:I246.
46.
KaplonRMichlerRXuHKwiatkowskiPEdwardsNPlattJ. Absence of hyperacute rejection in newborn pig-to-baboon cardiac xenografts. Transplantation1995;59:1–6.
